Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

NCT02919501 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: Vortioxetine (IV)
OTHER: Placebo (IV)
DRUG: Vortioxetine (tablet)

Sponsor

H. Lundbeck A/S

Collaborators

[object Object]